Full Press Release Details
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses.
IONS
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Key Takeaway: Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Price reaction · baseline $73.82 (2026-06-03 close) · hit after-hours · 2 other IONS headline(s) in the window, move may be shared
day 0 close · peak
+1.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+3%
120-day peak, hindsight
Typical move
3.7%
average across 15 past catalysts
Lead asset
ISIS 416858
Phase 2 · End-stage Renal Disease (ESRD)